Relmada Therapeutics Inc (RLMD)

Relmada Therapeutics' stock price has experienced significant volatility over the past six months, with a substantial increase of 505.04% followed by a recent decrease of 14.89%. Key events include Jefferies initiating coverage with a "Buy" recommendation on December 22, 2025, a regulatory update confirming FDA alignment on registrational studies design for NDV-01 on January 12, 2026, presentation of NDV-01 Phase 2 data on December 3, 2025, reporting Third Quarter 2025 financial results on November 13, 2025, pricing of a $100 million underwritten offering of common stock on November 4, 2025, and a sell signal issued on December 31, 2025.

As a clinical-stage biotechnology company, Relmada Therapeutics' products are still in clinical trials and not yet commercially available, so traditional demand seasonality is not applicable. The company's focus is on advancing its pipeline through clinical development and regulatory milestones.

Relmada Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing treatments for central nervous system diseases and other disorders, operating in the Pharmaceuticals: Major industry. Its primary product candidates include Esmethadone for CNS diseases, NDV-01 for non-muscle invasive bladder cancer with a Phase 3 trial planned for the first half of 2026, Sepranolone for Prader-Willi Syndrome and other disorders, and REL-P11 for metabolic disease.

Relmada Therapeutics, Inc. is headquartered in Coral Gables, Florida, United States. The company's operations and focus are primarily within the United States.

Relmada Therapeutics' brand reputation is viewed with a "Buy" consensus among analysts, with an average target price of $9.00. Jefferies initiated coverage with a "Buy" rating in December 2025. Zacks Investment Research rates Relmada Therapeutics as a Zacks Rank 3 ("Hold"), expecting an inline return relative to the market. The company emphasizes its dedication to developing innovative treatments and highlights its seasoned leadership team and scientific advisory board.

Relmada Therapeutics, Inc. has 49 institutional owners and shareholders holding a total of 9,002,015 shares. Major institutional owners include Ikarian Capital, LLC, Vanguard Group Inc., and Driehaus Capital Management Llc, among others.